Astera Labs no longer looks expensive after falling 50% from its highs, trading below 35x NTM EBITDA with EBITDA expected to grow at a 60% CAGR for several years. Revenue is growing 105% YoY, with growth expected to accelerate for the next 2-3 quarters as margins expand. The stock is testing key support at its September 2025 highs, just above the 0.618 Fibonacci level and 200-day EMA. It is worth a look if the AI infrastructure buildout continues as planned. x.com 

Astera Labs' key fundamentals are positive and growing nicely while the stock sits 35% off its highs, consolidating back toward its 200-day moving average. Ideal buying or accumulation is near or just above that average. x.com 

Astera Labs is an amazing business, but its valuation is getting quite pricey. x.com 

Astera Labs' growth is outrunning its share price: after recent earnings, it trades at nearly half the valuation it had at the same share price before. x.com 

Astera Labs is an invisible hero of AI, as its retimers and fabric switches let thousands of GPUs operate as one massive supercomputer. Demand for its solutions has grown manyfold over the past year, driving explosive revenue growth, despite last year's fears that efficient models like DeepSeek would hurt AI infrastructure names. x.com 

Astera Labs looks relatively expensive because similarly fast-growing AI infrastructure names trade at much lower multiples. Broadcom and Nvidia are at 14x, Credo at 15x and Lumentum at 18x; comparable peers look 50-80% cheaper. Astera is a great company and not necessarily expensive in absolute terms. Its roughly 2x multiple over Credo may persist, but the setup looks harder; with no valuation support, it could fall 50% if weakness continues. x.com  x.com  x.com  x.com 

Astera Labs is the next potential 10x long-term play for a young investor with high risk tolerance, as a leader in AI infrastructure connectivity whose semiconductor solutions power hyperscalers' rack-scale systems. x.com 

Astera Labs is a steal and an institutional favorite in the making, with a price target of $330 by late 2027. Revenue growth is pushing toward 80% this year, faster than expected, with free cash flow scaling toward about $480M and no debt. Its optical cabling push should compress non-GAAP gross margins by about 300 basis points, and the optics revenue payoff won't be meaningful until late 2027, which could bring near-term volatility. x.com 

Astera Labs is an incredible business, but its price leaves little margin of safety. Even an amazing decade, with revenue reaching $20B at 26% annual growth from about $1.9B, a 35% operating margin and a 30x multiple, makes it a roughly $158B company, about 3.6x from $44B, or around 13% a year before dilution. Slower revenue, lower margins, a lost customer, hyperscaler insourcing or tougher competition would erode that. Buying at half the price would make the risk/reward look amazing. x.com  … Show more

Credo is the better pick for momentum and potential returns right now, since a smaller market cap gives more torque, even though Astera Labs is fundamentally the better company. Scale-up connectivity will not be a big part of Credo's business until around FY28, so it needs to pivot into optics, while Astera is more agnostic and flexible. x.com